Acute myeloid leukemia (AML) often harbors mutations in epigenetic regulators, and also has frequent DNA hypermethylation, including the presence of CpG island methylator phenotypes (CIMPs). Although global hypomethylation is well known in cancer, the question of whether distinct demethylator phenotypes (DMPs) exist remains unanswered. Using Illumina 450k arrays for 194 patients from The Cancer Genome Atlas, we identified two distinct DMPs by hierarchical clustering: DMP.1 and DMP.2. DMP.1 cases harbored mutations in NPM1 (94%), FLT3 (71%) and DNMT3A (61%). Surprisingly, only 40% of patients with DNMT3A mutations were DMP.1, which has implications for mechanisms of transformation by this mutation. In contrast, DMP.2 AML was comprised of patients with t(8;21), inv(16) or t(15;17), suggesting common methylation defects connect these disparate rearrangements. RNA-seq revealed upregulated genes functioning in immune response (DMP.1) and development (DMP.2). We confirmed these findings by integrating independent 450k data sets (236 additional cases), and found prognostic effects by DMP status, independent of age and cytogenetics. The existence of DMPs has implications for AML pathogenesis and may augment existing tools in risk stratification.
Introduction
Epigenetic control of cell fate has long been studied in the context of organism development and cancer with nonrandom DNA methylation marks controlling various differentiation states [1, 2] . Aberrant hypermethylation has been shown to affect tumor-suppressor genes in cancer, and widespread hypermethylation defining a CpG island methylator phenotype (CIMP) can be observed in many tumor types [3] [4] [5] [6] . Many examples of specific DNA hypermethylation states have been shown to have clinical consequences in terms of therapy response and prognosis [6] [7] [8] . Loss of DNA methylation in cancer has also been widely described for many years, however, the genomic targets, causes and consequences of DNA demethylation remain unclear [9] .
Acute myeloid leukemia (AML) is a heterogeneous and lethal disease in which studying the DNA methylome is a promising avenue for understanding cancer epigenetics and for clinically stratifying patients. Although the overall somatic mutation burden in AML is low, some of the most frequently altered genes are epigenetic regulators. Approximately 25% of AML cases harbor mutations in the DNA methylation writer, DNMT3A [10] . Mutations in the demethylase, TET2 have been reported in~10% of cases, and IDH1/2 mutations occur in 10-15% of AML [10] . Each of these genes has been reported to affect the leukemic methylome. DNMT3A has been shown to drive hypomethylation in the context of FLT3-ITD mutations [11, 12] . TET2 has been reported to cause targeted DNA demethylation in some differentiation-related regions, and IDH1/2 mutations have been associated with oncometabolite formation causing hypermethylation via a TET-dependent mechanism [13] . In addition, our group recently identified a TET2-associated (TET2-DMC-low) profile and a mutationindependent hypermethylation signature (A-CIMP) associated with favorable outcomes [6, 14] .
In this study, we sought to identify and characterize distinct DNA demethylator phenotypes (DMPs) in AML. To this end, we studied The Cancer Genome Atlas (TCGA) AML samples profiled for DNA methylation, genetic mutations, gene expression and clinical outcomes, and identified two distinct DMPs with important mechanistic and clinical implications in AML biology. We validated our findings in independent data and propose that DMPs may be used to augment existing clinical features for patient risk stratification and for understanding AML pathogenesis.
Methods

DNA methylation array data
DNA methylation data on the Illumina HumanMethylation 450k array platform were obtained for 194 AML patient samples from the TCGA data portal [10] . Methylation data for 24 normal peripheral blood samples (GSE51388) were used to identify CpG sites, which are normally methylated [15] . Pre-processing of level 1 data was done using functional normalization implemented by the minfi R package [16] . We excluded CpG sites with NA values and were left with 375,324 sites for analysis. In order to enrich for sites which lose methylation in cancer, we applied filtering criteria to obtain the subset of probes which show variable methylation in AML but high methylation in normal blood (average beta-value > 0.8 in normal blood and beta-value standard deviation > 0.2 in AML). To extend our analysis and increase statistical power for validation, we merged multiple AML sample cohorts (TARGET, GSE62298, GSE58477 and GSE64934) interrogated with Illumina 450k arrays to compile a superset of 236 additional cases [10, 11, [17] [18] [19] . We merged tables of beta values for these cases using R. To identify previously published epigenetic signatures, we performed hierarchical clustering of the cases on methylation status of CpG sites for A-CIMP, I-CIMP and TET2-DMC [6, 14] . To test for the methylation status of differentiated leukocyte fractions, we used data on the 450k array for both myeloid and lymphoid lineages (GSE35069) and selected for CpG sites of interest using R [20] .
Characterizing hypomethylated CpG sites for protein binding and LINE-1 elements
Hypomethylated CpG sites were queried for protein binding using ChIP-seq peak data for CTCF in normal CD34 +hematopoietic progenitors, and SPI1 (PU.1) in HL-60 cells. Data were downloaded from the UCSC genome browser and peaks were overlapped with CpG sites interrogated by the Illumina 450k platform using hg19 probe coordinates in BED format with the intersection function in the Table Browser [21, 22] . LINE-1 repetitive elements were mapped to CpG sites measured by the 450k array using RepeatMasker [23] .
RNA-seq analysis
Level 3 RNA-seq data (per-gene read counts) were obtained for 176 available cases from the TCGA data portal [10] . Count data were processed with the edgeR package to determine differential expression [24, 25] . Genes identified as significantly upregulated in demethylator AML clusters were queried for functional annotation enrichments using GeneCoDis [26] [27] [28] . GeneCoDis annotations for biological process, molecular function and transcription factors were analyzed with a false discovery rate (FDR)-corrected hypergeometric test. We filtered the annotations for those with at least three query genes present.
Statistics
Unsupervised hierarchical clustering was performed in R using Ward's method implemented in the hclust function [29] . Comparisons for binary variables (e.g., mutation status) across groups were tested using Fisher's exact test. Continuous clinical variables (e.g., age and blast count) were compared using Student's t-tests. Kaplan-Meier and Cox regression analyses were done using the survival package in R [30] . Differences in Kaplan-Meier curves were compared using the log-rank test. Quantitative DNA methylation differences were defined as a difference in average beta-value across conditions >0.1 and an FDR < 0.05. Differential expression analysis for RNA-seq data was done using the edgeR package and significance was defined as an FDR-corrected P-value < 0.05 with a fold-change of 2. Odds ratios for context-specific DNA hypomethylation (e.g., LINE-1 repeats, gene bodies, etc.) were calculated in R using the following formula: 
Data availability
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Results
Distinct DMPs in subsets of AML patients
To study the associations between DNA hypomethylation and AML biology, we analyzed Illumina 450k arrays interrogating 194 TCGA leukemia samples. Patient characteristics are presented in Supplementary Table S1 . To enrich for CpG sites that lose methylation (i.e., 'demethylate') in cancer, we selected for those with high methylation in normal peripheral blood, and variable methylation across the AML cohort (see Methods section). Hierarchical clustering of the samples based on these 2606 sites revealed two distinct groups showing profound hypomethylation: DMP.1 and DMP.2 (Fig. 1a ). Analysis of the distributions of DNA methylation levels for these clusters showed a significant shift of density to lower values ( Fig. 1b) . To rule-out potential cell of origin artifacts, we performed the same analysis using data obtained from bone marrow-derived hematopoietic stem cells as the normal comparator and obtained similar results (Supplementary Figure S1 ). For downstream exploration of DMP biology, we refined a classifier of each DMP using differential methylation analysis ( Fig. 1c ). From this, we identified signatures of 213 DMP.2 CpG target sites and 811 DMP.1 target sites (FDR < 0.05 and beta-value difference > 0.2; Supplementary  Tables S2 and S3 ). Re-classifying the AML samples on the DMP.1 targets revealed a cluster of 31 DMP.1 patients, and the remaining 163 were DMP.1 negative (DMP.1-neg; Fig. 1d , top). The same analysis done using the DMP.2 markers identified groups of 38 DMP.2 and 156 DMP.2negative (DMP.2-neg) cases (Fig. 1d, bottom) . Importantly, DMP.2 and DMP.1 were mutually exclusive phenotypes (i.e., no cases were identified as both DMP.2 and DMP.1).
Genome-wide DNA methylation specificity in DMP+ AML
From a DNA methylation perspective, we next sought to explore the features of all interrogated genomic loci, not just those selected by the initial filtering criteria. To this end, we performed differential methylation analysis for DMP.1 and DMP.2 for specific genomic compartments. Using an average beta-value difference threshold of 0.1 with an FDR < 0.05, we identified 3857 sites in CGIs and 31,763 sites in non-CGIs that lose methylation in DMP.1 AML compared with DMP.1-neg ( Fig. 1e, top) . There was also a relatively small number of CpG sites that gained methylation in DMP.1 (Fig. 1e, top) . The same analysis for DMP.2 revealed 3504, and 9530 CGI and non-CGI sites, respectively, which lost methylation compared with DMP.2-neg (Fig. 1e, bottom) . In contrast to DMP.1, however, DMP.2 leukemias demonstrated relatively more hypermethylation compared with DMP.2-neg (1250 and 5029 CpGs in CGI and non-CGI regions, respectively; Fig. 1e, bottom) . We performed a genomic localization enrichment analysis using odds ratios to identify whether certain features (e.g., CGIs, non-CGIs) were more or less likely to demethylate in DMPs compared with DMP-neg leukemias (see Methods section). This analysis revealed that DMP.1 demethylation is more pronounced overall compared with DMP.2 by virtue of higher magnitude odds ratios, however, DMP.2 showed more specificity for CGI (vs. non-CGI) demethylation ( Fig. 1f ). An extended analysis of odds ratios for demethylation revealed no specificity for promoters, enhancers, gene bodies, LINE-1 repetitive elements, PU.1-binding sites or CTCF-binding sites for either DMP, but that the magnitude of enrichments at regulatory elements was generally higher for DMP.1-that is, the odds ratios were generally higher for DMP.1 sites compared with DMP.2 sites (Supplementary Figure S2 ).
DMP status is associated with DNMT3A mutations and cytogenetic risk
We examined somatic alterations present in the DMPs and found that compared with DMP-neg, the DMP.1 cases were significantly enriched for mutations in DNMT3A, and FLT3 (61% vs. 22% and 71% vs. 17%, respectively, Fisher's exact P < 0.001; Fig. 2a ). Strikingly, nearly all DMP.1 cases also harbored mutations in NPM1 (94% vs. 19%, Fisher's exact P < 0.001; Fig. 2a ). In contrast, DMP.2 cases were characterized by a relative absence of somatic mutations, which was statistically significant for DNMT3A, NPM1, IDH1, IDH2 and TP53. (0% vs. 22%, 19%, 13%, 14% and 13%; Fisher's exact P < 0.001, < 0.001, = 0.04, < 0.01 and < 0.01, respectively; Fig. 2a ). Genomic rearrangements were also significantly different between DMPs, with DMP.1 cases showing significant enrichment for intermediate cytogenetic risk, and no cases harboring any favorable risk abnormality ( Fig. 2a ). DMP.2, however, was characterized by all except one case harboring either t(8;21), inv (16) or t(15;17), suggesting a common epigenetic link between different good-risk cytogenetic aberrations (97% vs. 0%, Fisher's exact P < 0.001; Fig. 2a ). Within DMP.2, the three cytogenetic abnormalities clustered separately by DNA methylation, with many CpG sites losing methylation in all cases, and a subset showing less demethylation in t (15;17)-positive cases (Supplementary Figure S3a) .
We next analyzed the data for the presence or absence of known epigenetic signatures; A-CIMP and TET2-DMC-low are favorable prognostic factors, whereas I-CIMP is a nonprognostic hypermethylation profile associated with IDH1/2 mutations ( Supplementary Table S4 -S6) [6, 14] . In this analysis, we found both DMPs to be I-CIMP-negative (0% in both vs. 22% in DMP-neg; Fisher's Exact P < 0.001), but DMP.2 cases were enriched for A-CIMP, and almost entirely overlapping with TET2-DMC-low (42% vs. 18%, and 89% vs. 3%; Fisher's Exact P < 0.01, < 0.001, respectively; Fig. 2a ). The enrichment for A-CIMP+leukemias in DMP.2 is consistent with the observed DNA methylation data (Fig. 1e, bottom) ; CpG sites, which have low methylation in normal blood hypermethylate readily, while sites with high methylation in normal blood demethylate in this context, suggesting a widespread reprogramming phenomenon in CGI DNA methylation.
The observed co-occurrence and mutual exclusivity of different genetic mutations in DMP+ cases also revealed striking patterns. DMP.1 AML was enriched for cooccurrence of NPM1, FLT3 and DNMT3A mutations (Fig. 2b) . In contrast, nearly every DMP.2 case had one of three recurring favorable risk rearrangements. The sole outlier case was positive for A-CIMP, TET2-DMC-low and a FLT3 mutation, but lacked other common alterations in AML (Fig. 2c) .
From a clinical perspective, we also observed important differences between DMP.1, DMP.2 and DMP-neg. Bone marrow blast percentage did not differ by DMP status, however, both DMP.1 and DMP.2 patients were significantly younger compared with DMP-neg, with DMP.2 patients being the youngest (median age, years: DMP.1 = 55, DMP.2 = 49.5, DMP-neg = 61; P < 0.001; Fig. 2a ). In addition, Kaplan-Meier survival analysis demonstrated DMP.1 status was not associated with overall survival (OS) in this cohort (median OS, months: DMP.1 = 11.5, DMP.1neg = 19; log-rank P = 0.51; Fig. 2e ), but DMP.2 leukemia patients had significantly improved OS (median OS, months: DMP.1 = 11.5, DMP.2 = not reached, DMP-neg = 12.4; log-rank P < 0.001; Fig. 2e ). Because of the nearperfect overlap between methylation and cytogenetic risk, we could not assess whether their prognostic effects were independent in this data set. When we examined whether there were differences between cytogenetic groups within DMP.2, we found that neither genetic mutations, nor OS varied by specific cytogenetic rearrangement (median OS, months: t(15;17) = not reached, t(8;21) = 30.6, inv(16) = not reached, other = not reached; log-rank P = 0.77; Supplementary Figure S3b ). Furthermore, the subset of DMP.2 FLT3 mutation-positive cases did not have significantly different outcomes compared with FLT3 wild-type cases (median OS, months: FLT3-ITD = not reached, FLT3-TKD = not reached, wild-type = not reached; log-rank P = 0.75; Supplementary Figure S3c ).
DNMT3A mutated AML is not always DMP.1
Given the observation that many DNMT3A mutant cases are DMP-neg, we sought to characterize this interesting subset (Fig. 2d ). We isolated the DNMT3A mutant leukemias and found that only 19/47 (40%) were DMP.1, with the rest being DMP.1-neg ( Fig. 3a) . From a genetic perspective, we found that the DMP.1-neg leukemias had a mix of the canonical DNMT3A R882 mutations, and non-R882 mutations ( Fig. 3a) . Importantly, the DMP.1-neg cases also often had co-occurring mutations in IDH1, IDH2 or TET2-three genes reported to cause aberrant hypermethylation-and relatively few FLT3 mutations (Fig. 3a) . We tested these observations statistically and found that the enrichments for IDH1, IDH2 and TET2 were not individually significant, but reached significance when aggregated (57% in DMP.1neg vs. 16% in DMP.1; Fisher's exact P = 0.006; Fig. 3b ). This analysis also revealed significantly fewer mutations in FLT3 and NPM1 in DMP.1-neg AML (14% in DMP.1-neg vs. 84% in DMP.1 and 32% in DMP.1-neg vs. 95% in DMP.1, respectively; Fisher's exact P < 0.001 for each; Fig. 3b ). From a clinical perspective, the DNMT3A mutant cases did not differ in OS by DMP.1 status (median OS, months: DMP.1 = 8.2, DMP.1-neg = 12.0; log-rank P = 0.98; Fig. 3c ).
DMP.1 and DMP.2 AML have distinct gene expression signatures
To examine the transcriptomic differences between DMP.1 and DMP.2, we studied gene expression changes measured by RNA-seq. We performed differential expression analysis using edgeR (see methods) comparing DMP.1 with DMP.1neg, and DMP.2 to DMP.2-neg and found there was generally more transcriptional upregulation than downregulation in both DMPs. In DMP.1 leukemias, we identified 236 genes significantly upregulated and 68 downregulated compared with DMP.1-neg (FDR < 0.05; fold-change > 2; Fig. 4a ). For DMP.2 AML, 310 genes were upregulated and 83 were downregulated (FDR < 0.05; foldchange > 2; Fig. 4c ). Importantly, the differentially expressed genes identified between the two DMPs were entirely mutually exclusive.
Performing a gene set enrichment analysis for the upregulated genes revealed that both DMPs had upregulated genes functioning in ion transport, but that cell-cell signaling, immune response, JUN and GATA1 target genes were specific to DMP.1, whereas gene ontology categories for development, FOXO4, LEF-1, ELSPBP1 and other transcription factor targets were specific to DMP.2 AML (Figs. 4b, d for DMP.1 and DMP.2, respectively).
We then tested whether there was a significant overlap between differentially methylated, and differentially expressed genes in this data set. For DMP.1 AML, 66 out of 236 upregulated genes were also found to be hypomethylated compared with DMP.1-neg (Fisher's exact P = 0.007). In contrast, only 16 of 310 upregulated genes in DMP.2 leukemias were also significantly hypomethylated relative to DMP.2-neg (Fisher's exact P = 0.48). This observation is consistent with the overall higher enrichments for DNA demethylation at regulatory elements for DMP.1 compared Figure S2) . Interestingly, gene set enrichment analysis of the subset of hypomethylated and upregulated genes further confirmed the association between DMP.1 and immune response genes, and DMP.2 and developmental genes ( Supplementary Tables S7 and S8 for DMP.1 and DMP.2, respectively). In addition, we queried DNA methylation status at DMP. 1 Figure S4) . We found that the CpG sites demethylated in both DMPs are mostly methylated in normal leukocyte fractions, however, there are subsets of these sites that show low methylation levels, most markedly in the lymphoid fractions, further suggesting that DMP.2 demethylation defines a phenotype poised for differentiation ( Supplementary Figure S4b) . In contrast, the DMP.1 CpG sites with low methylation in healthy leukocyte fractions also tended to have low methylation in BM-HSCs (Supplementary Figure S4a) .
and DMP.2 sites in multiple differentiated leukocyte fractions from healthy donors including NK cells, CD4+ T cells, CD8+ T cells, CD19+ B cells, CD14+ monocytes, granulocytes, neutrophils and eosinophils (Supplementary
Finally, we queried the RNA-seq data to explore gene expression levels of several known epigenetic regulators: DNMT1, DNMT3A, DNMT3B, TET1, TET2 and TET3 (Supplementary Figure S5) . Although there were subtle differences in expression of DNMT1 and TET1 across DMPs (Supplementary Figure S5a and S5d), the most striking result was significant downregulation of DNMT3A in DMP.1 leukemias with concurrent upregulation of TET2 ( Supplementary Figure S5b and S5e). The downregulation of DNMT3A did not vary according to mutation status. We also observed a significant downregulation of DNMT3B in DMP.2 AML (Supplementary Figure S5c ). There was a significant upregulation of myeloperoxidase (MPO) within this subset as well, consistent with data reported by Itonaga et al. suggesting that MPO is a key maturation marker of AML blasts (Supplementary Figure S5g) [31] . TET3 expression was statistically identical across the DMPs.
Validation of DMPs in independent methylation data
In order to validate our findings, we queried additional AML data sets on the 450k platform, including TARGET, GSE62298, GSE58477 and GSE64934 (see Methods . We integrated the validation data sets to form a superset consisting of 236 AML cases, and used our identified DMP signatures to classify the patient samples by hierarchical clustering. Based on DMP methylation status, we found groups of 50 and 45 leukemias positive for DMP.1 and DMP.2, respectively (Figs. 5a, b) . Consistent with our previous analyses, these phenotypes were mutually exclusive.
We then sought to characterize these cases based on genetic mutations and clinical outcomes. We confirmed relative enrichments for DNMT3A and NPM1 mutations in DMP.1, however, unlike in the TCGA cohort, the majority of cases did not harbor NPM1 mutations (57% vs. 5% in DMP-neg and 18% vs. 3% in DMP-neg, respectively; Fisher's exact P < 0.001, 0.06, for DNMT3A and NPM1, respectively; Fig. 5c ). We speculate this is due to the relative rarity of NPM1 mutations in the pediatric TARGET data set, however, DMP.1 leukemias still carried the highest percentage of mutations compared with DMP.2 and DMPneg. DMP.2 leukemias, in contrast, lacked DNMT3A mutations, and were significantly enriched for favorable cytogenetics, however, not all DMP.2 cases harbored these rearrangements (65% vs. 1% in DMP-neg; Fisher's exact P < 0.001; Fig. 5c ). We also examined DNMT3A mutant cases in isolation and found that 80% were positive for DMP.1. We further considered a recent study published by Cauchy et al., which identified a FLT3-associated epigenetic signature [18] . We sought to see whether the DMP.1 signature could recapitulate this FLT3 phenotype by hierarchical clustering of DNA methylation for the AML cases published in the Cauchy study, and found that demethylation of the DMP.1 sites was present in two Figure S6 ). Thus, it is likely that the FLT3 and DMP.1 DNA methylation signatures are independent. Importantly, within this external cohort, we confirmed that DMP.1 demethylation does not occur in cases with IDH1/2 or TET2 mutations (Supplementary Figure S6) .
In addition to validation of mutational signatures, we found that in this cohort DMP.1 patients had significantly inferior OS compared with DMP-neg, whereas patients with DMP.2 disease had significantly better outcomes (median OS, months: DMP.1 = 13.1, DMP.2 = not reached, DMPneg = 22.8; log-rank P < 0.001; Fig. 5d ). We also found that patients with intermediate or poor risk cytogenetic abnormalities who had DMP.2 disease had significantly better OS compared with DMP-neg (median OS, months: DMP.2 = not reached, DMP-neg = 20.3; log-rank P = 0.03; Supplementary Figure S7 ).
Because both DMPs were associated with survival and neither was completely defined by gene mutations, we tested whether the DNA methylation effects were independent from cytogenetics and age in this cohort. First, we performed univariate Cox regression analysis using available clinical covariates and gene mutations and found that only DMP status (DMP.1 hazard ratio (HR) = 2.00, 95% confidence interval (CI): 1.20-3.35, P = 0.008; DMP.2 HR = 0.38, 95% CI: 0.22-0.65, P = 0.001), age > 60 (HR = 2.37, 95% CI: 1.50-3.73, P < 0.001), and cytogenetic risk (HR = 1.94, 95% CI: 1.38-2.74, P < 0.001) were associated with outcome ( Fig. 5e ). In multivariate Cox regression models, both DMP.1 (HR = 1.69, 95% CI: 0.99-2.86, P = 0.05) and DMP.2 (HR = 0.49, 95% CI: 0.26-0.93, P = 0.03) were associated with survival independent of each other, age and cytogenetic risk (Fig. 5f ). These data suggest that DMP status may be useful to augment existing clinical covariates in stratifying patients with AML.
Discussion
Although numerous studies have investigated the complexities of aberrant hypermethylation in cancer, there is a relative gap in knowledge in the biology surrounding losses of DNA methylation. In this study, we interrogated genome-wide DNA methylation data to identify DMPs in AML. We found two distinct and non-overlapping DMPs: DMP.1 and DMP.2. Although both types of leukemia were characterized largely by demethylation of normally methylated non-CGI CpGs, the specific genomic targets of demethylation were non-random and were associated with gene expression, mutational and clinical signatures. Interestingly, the identification of DMP-positive leukemia did not materially differ between using normal bone marrowderived hematopoietic stem cells vs. normal whole peripheral blood as controls. This suggests that DMP demethylation is cancer specific, as the same CpG sites that lose methylation in DMP-positive AML are methylated in both normal peripheral blood cells (differentiated) and hematopoietic stem cells (undifferentiated).
The DMPs were genetically distinct with most DMP.2 patients harboring t(8;21), inv (16) or t (15;17) . In our validation cohort, approximately one-third of DMP.2 patients did not have one of these rearrangements, and importantly, the DMP.2 methylation profile was associated with better survival independent of cytogenetic risk. This result suggests that a possible epigenetic mechanism may underlie the improved curability in patients harboring good-risk genomic rearrangements. This possibility is further alluded to by the observed upregulation of genes enriched for organism development, and targets of specific hematopoietic transcription factors, including LEF-1 and GFI1 [32, 33] . The biological connection between the three cytogenetic abnormalities is likely a common differentiation "proneness". This is further supported by the observation that some DMP.2 CpG sites are demethylated in certain differentiated leukocyte fractions derived from healthy individuals. We speculate that leukemias harboring demethylation at these sites may be epigenetically poised to differentiate regardless of the specific cytogenetic rearrangement that led to transformation.
In contrast to DMP.2, DMP.1 was associated with relatively poor clinical outcomes and was enriched for cooccurring DNMT3A, NPM1 and FLT3 mutations. Although the role of DNMT3A in writing DNA methylation marks is well-established, the strong association between NPM1 mutations and DNA demethylation may merit further investigation into a possible mechanistic relationship. In addition, we identified an intriguing subset of DNMT3A mutation-positive leukemias, which did not demethylate at DMP.1 CpG sites. These cases showed an enrichment for mutations in IDH1, IDH2 and TET2, all of which have been previously implicated in hypermethylation in cancer [6, 13, 34] . Of equal interest, this same population of patients lacks hypermethylation at I-CIMP CpG sites, suggesting a possible co-dependency between DNMT3A and TET demethylases in regulating the methylome. RNA-seq data support this speculation by virtue of marked downregulation of DNMT3A with upregulation of TET2 in DMP.1 leukemias. The fact that DNMT3A mutant AML does not necessarily show global hypomethylation and that IDH1/2 mutant AML does not necessarily show hypermethylation raise questions as to methylation independent mechanisms of transformation by these mutations. Indeed, it was recently reported that a RAS signaling signature was upregulated in IDH and DNMT3A co-mutated leukemias, and that patient-derived primary cells were sensitive to MEK inhibition [35] .
In addition to epigenetic regulators, the other key transcriptomic finding in DMP.1 AML was upregulation of immune response genes. Based on analysis of transcriptomic data alone, immune activation and viral response were among the most significantly enriched functions, with specific genes including the chemokines CXCL9 and CXCL10, and interleukins IL-3 and IL-15. Analysis of genes, which were both upregulated and hypomethylated, confirmed this functional enrichment. Thus, the transcriptional programs of DMP.1 and DMP.2 are distinct, and may contribute to leukemia, which is primed to proliferate via an immune response profile in the case of DMP.1, or primed to differentiate in the case of DMP.2, thereby contributing to their clinical differences [36, 37] .
In summary, we present evidence of two DNA demethylation signatures in AML, which have mutually exclusive genetic backgrounds and clinical characteristics. Our data suggest an epigenetic link between different good-risk genomic rearrangements, and a methylation profile associated with DNMT3A mutations, and upregulation of immune response genes. We found that both DMPs were prognostic-independent of age and cytogenetic risk-in an independent validation cohort. Future studies should validate the clinical relevance of these DMP signatures and attempt to integrate them with other established risk markers, and DNA methylation profiles in AML. In addition, the possible interactions between DNMT3A mutations and TET demethylases should be further explored from a molecular mechanistic perspective. More globally, the presence of DMPs in cancer add to the complexity of epigenetic deregulation and should be examined across all cancer types in the same way CIMP was examined by the TCGA.
